Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.54 |
| ▸ | GCG | P01275 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951398 | 1.00 | GCGR (0.54) | GCGRGCGLMNAITGB1ITGA4 | |
| SCHEMBL9950990 | 0.91 | GCGR (0.61) | GCGRGCGLMNAITGB1ITGA4 | |
| SCHEMBL9951565 | 0.91 | GCGR (0.58) | GCGRGCGITGB1ITGA4HCAR3 | |
| SCHEMBL9951561 | 0.91 | GCGR (0.58) | GCGRGCGITGB1ITGA4HCAR3 | |
| SCHEMBL9951339 | 0.86 | GCGR (0.71) | GCGRGCGLMNAITGB1ITGA4 | |
| SCHEMBL9952265 | 0.84 | GCGR (0.77) | GCGRGCG | |
| SCHEMBL9951708 | 0.84 | GCGR (0.77) | GCGRGCG | |
| SCHEMBL9951763 | 0.84 | GCGR (0.55) | GCGRGCG | |
| SCHEMBL10199918 | 0.83 | GCGR (0.63) | GCGRGCG | |
| SCHEMBL9951730 | 0.81 | GCGR (0.65) | GCGRGCGHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8933104-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329862-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329862-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCGR 2/4885GCG 15/4885LMNA 2805/4885 |
| US-20150094338-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCGR 2/4885GCG 15/4885LMNA 2805/4885 |
| US-20120165343-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCGR 2/4885GCG 15/4885LMNA 2805/4885 |
| US-20150266861-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | GCGR 2/4885GCG 15/4885LMNA 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.